DTP-HepB vaccine

DTP-HepB
Combination of
DTP vaccineVaccine
Hepatitis B vaccineVaccine
Names
Trade namesTritanrix-HepB
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use
Intramuscular injection
External links
AHFS/Drugs.comUK Drug Information
Identifiers
CAS Number
  • 1012056-47-1
ATC code

DTP-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and whole-cell pertussis and hepatitis B (recombinant) vaccine (adsorbed) or DTP-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, and hepatitis B.[1]

A branded formulation, Tritanrix-HepB manufactured by GlaxoSmithKline, was granted marketing approval in the EU in 1996. Marketing approval lapsed in 2014.[2]

A review conducted in 2012 concluded that there was insufficient evidence to determine differences in safety and efficacy between DTP-HepB vaccine and Hib vaccine administered separately and pentavalent DTP-HepB-Hib vaccine.[3]

References

  1. World Health Organization; World Health Organization Department of Immunization, Vaccines and Biologicals (2004). Immunization in Practice: A Practical Guide for Health Staff. World Health Organization. p. 18. ISBN 9789241546515. Archived from the original on 11 January 2022. Retrieved 15 July 2018.
  2. "Tritanrix HepB". European Medicines Agency. Archived from the original on 15 July 2018. Retrieved 14 July 2018.
  3. Bar-On ES, Goldberg E, Hellmann S, Leibovici L (April 2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". The Cochrane Database of Systematic Reviews. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.